Whanin Pharm Asset Resilience Ratio
Whanin Pharm asset resilience ratio. Whanin Pharm (016580) has an Asset Resilience Ratio of 2.08% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Whanin Pharm to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Whanin Pharm (2009–2025)
Asset resilience ratio of Whanin Pharm from 2009 to 2025. This chart shows how Whanin Pharm's Asset Resilience Ratio has changed over time. Read debt load of Whanin Pharm for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Whanin Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Whanin Pharm.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩10.01 Billion | 2.08% |
| Total Liquid Assets | ₩10.01 Billion | 2.08% |
Asset Resilience Insights
- Limited Liquidity: Whanin Pharm maintains only 2.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Whanin Pharm Industry Peers by Asset Resilience Ratio
Compare Whanin Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Whanin Pharm Asset Resilience Ratio by Year (2009–2025)
Whanin Pharm asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Whanin Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | ₩140.00 Million ≈ $94.88K |
₩478.89 Billion ≈ $324.54 Million |
-2.19pp |
| 2024-12-31 | 2.22% | ₩9.43 Billion ≈ $6.39 Million |
₩424.71 Billion ≈ $287.82 Million |
-6.03pp |
| 2023-12-31 | 8.25% | ₩33.09 Billion ≈ $22.43 Million |
₩401.23 Billion ≈ $271.91 Million |
-5.43pp |
| 2022-12-31 | 13.68% | ₩50.52 Billion ≈ $34.23 Million |
₩369.37 Billion ≈ $250.32 Million |
-9.51pp |
| 2021-12-31 | 23.19% | ₩81.91 Billion ≈ $55.51 Million |
₩353.19 Billion ≈ $239.35 Million |
-1.35pp |
| 2020-12-31 | 24.54% | ₩80.88 Billion ≈ $54.81 Million |
₩329.56 Billion ≈ $223.34 Million |
-6.26pp |
| 2019-12-31 | 30.80% | ₩93.90 Billion ≈ $63.63 Million |
₩304.88 Billion ≈ $206.62 Million |
+11.72pp |
| 2018-12-31 | 19.07% | ₩54.87 Billion ≈ $37.19 Million |
₩287.69 Billion ≈ $194.96 Million |
+4.25pp |
| 2017-12-31 | 14.82% | ₩40.74 Billion ≈ $27.61 Million |
₩274.84 Billion ≈ $186.25 Million |
+5.45pp |
| 2016-12-31 | 9.37% | ₩22.82 Billion ≈ $15.47 Million |
₩243.44 Billion ≈ $164.98 Million |
-0.98pp |
| 2012-12-31 | 10.35% | ₩18.78 Billion ≈ $12.73 Million |
₩181.43 Billion ≈ $122.95 Million |
-2.61pp |
| 2011-12-31 | 12.97% | ₩21.54 Billion ≈ $14.60 Million |
₩166.11 Billion ≈ $112.57 Million |
+3.03pp |
| 2009-12-31 | 9.93% | ₩11.81 Billion ≈ $8.01 Million |
₩118.95 Billion ≈ $80.61 Million |
-- |
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, an… Read more